Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis.
In conclusion, our findings support CTP as the optimum neoadjuvant regimen for HER2-positive breast cancer, with the best pCR and acceptable toxicity compared with CT. MP provides a therapeutic option for patients with poor performance status.
PMID: 31015833 [PubMed]
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
More News: Breast Cancer | Breast Conservation Surgery | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Hormones | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Toxicology